Literature DB >> 12890498

AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4).

Keishi Kanno1, Susumu Tazuma, Kazuaki Chayama.   

Abstract

The renin-angiotensin system has been shown to contribute to fibrogenesis in varieties of organs, including the liver. Here, we investigated whether the angiotensin II type 1A receptor (AT1A) is implicated in the development of liver fibrosis, using AT1A-deficient and wild-type (WT) mice. After single dose of carbon tetrachloride (CCl(4)), there were no significant differences between two groups with regard to hepatic inflammation and necrosis. After 4 weeks of treatment with CCl(4), histological examination revealed that AT1A-deficient mice showed less infiltration of inflammatory cells and less severe progression of liver fibrosis compared with WT mice. These findings were accompanied by the hepatic content of hydoxyproline and the expression of alpha-smooth muscle actin (alpha SMA). The level of transforming growth factor-beta 1 (TGF-beta 1) messenger RNA was markedly higher in WT mice when compared with AT1A-deficient mice. These results confirm that signaling via AT1A plays a pivotal role in hepatic fibrogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890498     DOI: 10.1016/s0006-291x(03)01357-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

1.  Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?

Authors:  Kathleen E Corey; Naga Chalasani
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

Review 2.  Animal models for the study of liver fibrosis: new insights from knockout mouse models.

Authors:  Hiromitsu Hayashi; Takao Sakai
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-02-24       Impact factor: 4.052

3.  Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression.

Authors:  Keishi Kanno; Susumu Tazuma; Tomoji Nishioka; Hideyuki Hyogo; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

Review 4.  Role of NADPH oxidases in liver fibrosis.

Authors:  Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner
Journal:  Antioxid Redox Signal       Date:  2014-01-24       Impact factor: 8.401

5.  Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2.

Authors:  Hitoshi Ikeda; Naoko Watanabe; Isao Ishii; Tatsuo Shimosawa; Yukio Kume; Tomoaki Tomiya; Yukiko Inoue; Takako Nishikawa; Natsuko Ohtomo; Yasushi Tanoue; Satoko Iitsuka; Ryoto Fujita; Masao Omata; Jerold Chun; Yutaka Yatomi
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

6.  Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model.

Authors:  Susanne Mende; Sigrid Schulte; Ingo Strack; Heike Hunt; Margarete Odenthal; Galyna Pryymachuck; Maria Quasdorff; Münevver Demir; Dirk Nierhoff; Hans-Peter Dienes; Tobias Goeser; Hans-Michael Steffen; Ulrich Töx
Journal:  Dig Dis Sci       Date:  2012-12-18       Impact factor: 3.199

7.  Effects of Yinchenhao decoction on self-regulation of renin-angiotensin system by targeting angiotensin converting enzyme 2 in bile duct-ligated rat liver.

Authors:  Lin Wu; Pi-Qi Zhou; Ji-Wen Xie; Rui Zhu; Sun-Chang Zhou; Geng Wang; Zhong-Xu Wu; Sha Hao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

8.  ANG II-AT1 receptor pathway is involved in the anti-fibrotic effect of beta-elemene.

Authors:  Rui Zhu; Ling Yang; Lin Shen; Jin Ye; Jianguo Liu; Shenjun Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

9.  Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice.

Authors:  Xiaopeng Li; Heather Rayford; Bruce D Uhal
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

10.  The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.

Authors:  Kathleen E Corey; Nirali Shah; Joseph Misdraji; Barham K Abu Dayyeh; Hui Zheng; Atul K Bhan; Raymond T Chung
Journal:  Liver Int       Date:  2009-02-09       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.